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Fatal congenital nonlysosomal cardiac glycogenosis has been attributed to a subtype of phosphorylase kinase
deficiency, but the underlying genes and mutations have not been identified. Analyzing four sporadic, unrelated
patients, we found no mutations either in the eight genes encoding phosphorylase kinase subunits or in the two
genes encoding the muscle and brain isoforms of glycogen phosphorylase. However, in three of five patients, we
identified identical heterozygous R531Q missense mutations of the PRKAG2 gene, which encodes the g2-subunit
of AMP-activated protein kinase, a key regulator of energy balance. Biochemical characterization of the recombinant
R531Q mutant protein showed 1100-fold reduction of binding affinities for the regulatory nucleotides AMP and
ATP but an enhanced basal activity and increased phosphorylation of the a-subunit. Other PRKAG2 missense
mutations were previously identified in patients with autosomal dominant hypertrophic cardiomyopathy with Wolff-
Parkinson-White syndrome, characterized by juvenile-to-adult clinical onset, moderate cardiac glycogenosis, dis-
turbed excitation conduction, risk of sudden cardiac death in midlife, and molecular perturbations that are similar
to—but less severe than—those observed for the R531Q mutation. Thus, recurrent heterozygous R531Q missense
mutations in PRKAG2 give rise to a massive nonlysosomal cardiac glycogenosis of fetal symptomatic onset and
rapidly fatal course, constituting a genotypically and clinically distinct variant of hypertrophic cardiomyopathy
with Wolff-Parkinson-White syndrome. R531Q and other PRKAG2 mutations enhance the basal activity and a-
subunit phosphorylation of AMP-activated protein kinase, explaining the dominant nature of PRKAG2 disease
mutations. Since not all cases displayed PRKAG2 mutations, fatal congenital nonlysosomal cardiac glycogenosis
seems to be genetically heterogeneous. However, the existence of a heart-specific primary phosphorylase kinase
deficiency is questionable, because no phosphorylase kinase mutations were found.
Introduction
Glycogen storage diseases (GSDs) with clinically promi-
nent cardiac involvement can be caused by various gene
defects. The lysosomal glycogenoses GSD II (Pompe dis-
ease [MIM #232300]) (with a-1,4-glucosidase deficiency)
and GSD IIb (Danon disease [MIM #300257]) (with ly-
sosome-associated membrane protein 2 [LAMP-2] defi-
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ciency) are systemic disorders that also affect either skel-
etal muscle, smooth muscle, and liver (GSD II) or skeletal
muscle and the nervous system (GSD IIb). However, car-
diac involvement usually dominates the clinical picture
and is life limiting in GSD IIb and in the classic infantile
form of GSD II, whereas the adolescent- and adult-onset
forms of GSD II are typically governed by muscle in-
volvement. The infantile form of GSD II has an autosomal
recessive mode of inheritance, manifests perinatally, and
leads to death within the 1st year of life (Hirschhorn and
Reuser 2001), whereas GSD IIb can be X-linked dominant
or recessive, has a juvenile or early-adult clinical onset,
and leads to death, typically during the 2nd to 4th decades
of life (Sugie et al. 2002; Arad et al. 2005). There appears
to be a distinct third type of lysosomal cardiac and skeletal
muscle GSD, with normal a-1,4-glucosidase and LAMP-
2, an infantile-fatal course, and an unidentified gene defect
(Yamamoto et al. 2001).
Among the nonlysosomal glycogenoses, GSD III (Cori
or Forbes disease [MIM 232400]) (with debranching
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enzyme deficiency) and GSD IV (Andersen disease [MIM
#232500]) (with branching enzyme deficiency) are also
systemic disorders. Liver and/or (less frequently) muscle
involvement usually dominates the clinical picture (Chen
2001). However, patients with prominent cardiac in-
volvement (manifesting during the 1st or 2nd decade of
life) have also been reported (Servidei et al. 1987; Lee et
al. 1997; Ewert et al. 1999; Chen 2001).
Mutations in the PRKAG2 gene, encoding the g2-sub-
unit isoform of AMP-activated protein kinase (AMPK),
give rise to a moderate, essentially heart-specific, non-
lysosomal glycogenosis with clinical onset typically in late
adolescence or in the 3rd decade of life, ventricular pre-
excitation predisposing to supraventricular arrythmias,
mild-to-severe cardiac hypertrophy, enhanced risk of sud-
den cardiac death in midlife, and autosomal dominant
inheritance with full penetrance (familial hypertrophic
cardiomyopathy with Wolff-Parkinson-White syndrome
[FHC/WPWS {MIM #600858}]) (Blair et al. 2001; Gol-
lob et al. 2001a, 2001b, 2002; Arad et al. 2002, 2005).
The AMPK complex, which acts as a sensor of cellular
energy status, is a heterotrimer comprising a catalytic a-
subunit and regulatory b- and g-subunits (Hardie 2003,
2004). The g-subunits contain four tandem repeats of a
sequence motif first recognized by Bateman (1997) and
termed a “cystathionine b-synthase” (CBS) motif. These
have recently been shown to act in pairs to form two
binding sites (now termed “Bateman domains” [Kemp
2004]) for the regulatory nucleotides AMP and ATP
(Scott et al. 2004). Binding of AMP (a signal of cellular
energy deficiency [Hardie and Hawley 2001]) causes ac-
tivation of the complex by triggering increased phos-
phorylation of a specific threonine residue (Thr-172) in
the kinase domain on the a-subunit by a distinct up-
stream kinase, an effect antagonized by high concentra-
tions of the inhibitory nucleotide ATP (Hawley et al.
1996). The major upstream kinase has recently been iden-
tified to be the tumor suppressor LKB1 (Hawley et al.
2003; Woods et al. 2003; Shaw et al. 2004). Once ac-
tivated by cellular stresses that deplete ATP and raise the
concentration of AMP, AMPK switches on various ATP-
producing catabolic pathways (including glucose uptake
and fatty-acid oxidation) and, conversely, down-regu-
lates ATP-consuming processes (Hardie and Hawley
2001; Kemp 2004; Scott et al. 2004). All seven distinct
FHC/WPWS mutations in the PRKAG2 gene identified
to date were either heterozygous missense mutations or
an insertion of a single amino acid within the Bateman
domain region. At least four of the seven mutations have
been shown to interfere with binding of the regulatory
nucleotides AMP and ATP (Scott et al. 2004) and with
activation of the complex by AMP (Daniel and Carling
2002; Scott et al. 2004). However, since these are loss-
of-function effects, it has been difficult to explain why
these mutations are dominant in vivo.
Rare, sporadic cases of severe prenatal- or neonatal-
onset nonlysosomal cardiac glycogenosis—which leads
to death within a few weeks to a few months after birth,
through heart failure and respiratory compromise—
have been attributed to a heart-specific variant of phos-
phorylase kinase (Phk) deficiency (MIM 261740) (Mi-
zuta et al. 1984; Eishi et al. 1985; Servidei et al. 1988;
Elleder et al. 1993; Regalado et al. 1999; Bu¨hrer et al.
2003). Phk is a regulatory protein kinase that stimulates
glycogen breakdown in response to neural and endo-
crine signals by phosphorylating and activating the
main glycogen-catabolizing enzyme, glycogen phospho-
rylase. It is composed of four subunits in a hexadeca-
meric complex, (abgd)4, in which the d-subunit is cal-
modulin, and it exists in numerous isoforms and splice
variants. Two distinct genes encoding muscle and liver
isoforms occur for both a and g, a single gene occurs
for b, and three genes encode identical calmodulin poly-
peptides. Genetic deficiency of Phk underlies a group of
GSDs that differ in mode of inheritance and tissue in-
volvement, depending on the mutant subunit gene. aM
(PHKA1) mutations cause X-linked recessive muscle
glycogenosis, aL (PHKA2) mutations cause X-linked re-
cessive liver glycogenosis, b (PHKB) mutations give rise
to autosomal recessive glycogenosis of both liver and
muscle but with an essentially liver-specific clinical phe-
notype, and gTL (PHKG2) mutations underlie autoso-
mal recessive liver glycogenosis with a particularly se-
vere phenotype and a higher risk of cirrhosis (Kilimann
1997; Chen 2001). No mutations have been identified
yet in the gM (PHKG1) gene, but they would be antic-
ipated to cause an autosomal recessive muscle glyco-
genosis. A molecular explanation for an infantile-fatal,
heart-specific, nonlysosomal glycogenosis with low Phk
activity, however, has been lacking. Unlike the other
forms of Phk deficiency, in which the tissue specificity
of expression of the subunit isoforms provided guidance
to the identification of the affected genes, no Phk gene
sequences expressed specifically in the heart are known.
However, particular missense mutations or genetic
backgrounds could give rise to phenotypes of unantic-
ipated tissue specificity, even though more widely ex-
pressed gene sequences are affected, as observed in other
GSDs (Servidei et al. 1987; Ewert et al. 1999; Ziemssen
et al. 2000; Chen 2001).
Here, we report the molecular genetic analysis of a
group of sporadic patients with fatal congenital non-
lysosomal cardiac glycogenosis and a biochemical di-
agnosis of cardiac Phk deficiency. The complete coding
sequences of all eight genes encoding Phk subunits (in-
cluding calmodulin) and of the two genes for the muscle
and brain isoforms of glycogen phosphorylase were an-
alyzed. When we found no mutations in the Phk or phos-
phorylase genes, we also analyzed the PRKAG2 gene. In
three of five cases, the disease was associated with a
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unique, recurrent heterozygous R531Q missense muta-
tion in PRKAG2. Biochemical analysis of the recombi-
nant mutant protein revealed stronger perturbations of
molecular properties than those of any other PRKAG2
mutation characterized to date.
Subjects and Methods
Case Reports
Detailed accounts of patients A, B (Regalado et al.
1999), and E (Bu¨hrer et al. 2003) have been published
elsewhere. In patient A (1200; case 1 in the study by Re-
galado et al. [1999]), a Hispanic American female, car-
diomegaly was detected in utero by ultrasound and echo-
cardiography, and worsening bradycardia prompted ces-
arean section at 31 wk of gestation. Shortly after birth,
the infant developed cardiorespiratory problems requiring
intubation. Electrocardiography (ECG) revealed a short
PR interval, wide QRS, inverted T waves, and ST ele-
vation. She experienced recurrent cardiac and respiratory
complications throughout her hospital course and suc-
cumbed at age mo to ventricular fibrillation. An au-32 4
topsy 10 h postmortem showed massive cardiomegaly
(136 g [normal 21 g]), with biventricular mural thickening
and effacement of both chambers. Other notable features
were macroglossia, faciocervical dysmorphism, enlarged
and dysmorphic kidneys, and an increased number of
pancreatic islets. Microscopically, periodic acid Schiff
(PAS) stain–positive and amylase-sensitive vacuolar gly-
cogen depositions were seen in heart tissue. Cardiac gly-
cogen concentration was 3.3% (control 0.9%), and car-
diac Phk activity was 0.001 U (control 0.34 U). Histo-
logical examination revealed no abnormal glycogen de-
position in skeletal muscle, tongue, kidneys, spleen, or
liver.
Patient B (1877; case 2 in the study by Regalado et
al. [1999]), a white American male, was delivered by
cesarean section because of breech presentation and non-
reassuring heart rate at 37 wk of gestation. He remained
ventilator dependent through most of his hospital course,
which was characterized by progressive cardiac enlarge-
ment (first noted at day 4 by chest X-ray), secondary
pulmonary compression, and oral feeding intolerance.
Increasing respiratory distress led to death at age 2 mo.
An autopsy at 11 h postmortem showed marked cardio-
megaly (65 g [normal 24 g  5 g]), with biventricular
mural thickening and effaced, slitlike chambers. Other
notable features were macroglossia and facial dysmorph-
ism, bilateral cataracts, enlarged kidneys, and hydroceph-
alus. Histological examination revealed abundant vacu-
olar, PAS-positive, amylase-sensitive glycogen deposition
in the heart. Cardiac glycogen was 3.1% (control 0.7%),
and cardiac Phk was 0.03 U (control 0.38 U). No his-
tological or histochemical evidence of abnormal glycogen
deposition was found in tissues other than the heart.
Patient C (JW), a white American male, was born at
full term by cesarean section because of breech presen-
tation. He developed cardiorespiratory failure within 30
min of life and required mechanical ventilation and, ul-
timately, extracorporeal membrane oxygenation. ECG
showed a normal PR interval, no delta wave, low QRS
voltages, and prominent ST wave elevations, consistent
with ischemia and/or a lateral wall infarct. Echocardio-
gram revealed severe left ventricular dysfunction with-
out hypertrophy or structural heart disease. His clinical
course was complicated by renal failure secondary to
hypotension. On day 10, he became less responsive and
developed unusual movements. Electroencephalogram
revealed a burst suppression pattern and seizure activity,
indicating a dismal prognosis. Support was withdrawn,
and he died on day 11. An autopsy at 2 h postmortem
consisted of limited biopsies of heart, liver, lung, skeletal
muscle, and kidney. Gross examination revealed no con-
genital malformations, but there was pulmonary con-
gestion with bilateral pleural effusions, anasarca, ascites,
a right occipital cephalohematoma, and incomplete,
broad palmar creases. Light microscopy revealed diffuse
vacuolization of the cardiac myofibers, but not of other
tissues. Electron microscopy showed abundant non–
membrane-bounded glycogen in cardiac myocytes and
a slight increase in non–membrane-bounded glycogen in
liver. Glycogen concentration was enhanced in the heart
(3.2% [control 0.5%]) and was normal in skeletal mus-
cle and liver. Phosphorylase kinase activity was 15% of
the control value in heart and 50%–60% of control values
in liver and skeletal muscle. Total phosphorylase and de-
branching enzyme activities were also ∼50% of control
values in all three tissues. Family history was notable for
a previous sister who had died at several hours of life
from respiratory failure, despite mechanical ventilation.
She had a loud systolic murmur, but no echocardiogram
could be obtained. She also had dysmorphic features (flat-
tened occiput, epicanthal folds, and nuchal folds, as well
as possible cystic hygroma, single palmar crease, and cli-
nodactyly), hypotonia, and large adrenals (determined by
ultrasound). Karyotype was normal, and autopsy was de-
clined. The parents (nonconsanguineous) and two other
siblings are unaffected.
Patient D (RB), a white British female, was delivered
at 37 wk of gestation by cesarean section because of
fetal bradycardia. The parents are nonconsanguineous,
and there are two previous healthy children. The baby
had problems with feeding, bradycardia, and recurrent
apnea in the 1st wk of life. She was not dysmorphic and
had normal peripheral power and tone and normal prim-
itive reflexes. There was no hepatomegaly. ECG showed
evidence of preventricular hypertrophy with a short PR
interval and very large QRS voltages in all leads. Chest
X-ray revealed massive cardiomegaly, and echocardio-
gram confirmed a severe hypertrophic cardiomyopathy.
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Despite medical management, she developed progressive
cardiac failure with pulmonary edema and hypotension
and died at age 34 d. An autopsy at 6 h postmortem
showed an extremely hypertrophic heart (124 g [normal
22 g]), which occupied the greater part of the thoracic
cavity. The walls of both atria and ventricles appeared
diffusely hypertrophic, smooth, and pale. The heart was
otherwise anatomically normal. The lungs were edem-
atous, and the liver was congested and focally hemor-
rhagic but not enlarged; the rest of the postmortem ex-
amination was unremarkable. Glycogen concentration
was elevated both in heart (2.4%) and in skeletal muscle
(2.9%). Phk was at 10% of the normal range mean in
liver and at 1% of the normal range mean in muscle and
was undetectable in heart, whereas total phosphorylase
was in the normal range in all tissues. Branching enzyme
was normal in liver and undetectable in muscle. a-Glu-
cosidase in cultured fibroblasts was normal.
Patient E (Bu¨hrer et al. 2003), a white male, the first
child of healthy nonconsanguineous German/Polish par-
ents, was delivered at 28 wk of gestation by cesarean
section after routine ultrasound examination detected
persistent bradycardia. Heart rate remained between 90
and 120 beats per min, despite adequate oxygenation.
An ECG revealed left-axis deviation, very short PQ in-
tervals (0.06 s), enlarged QRS complexes with delta
waves suggestive of WPWS, and depressed ST segments.
Echocardiography showed atrial and biventricular hy-
pertrophy without outflow obstruction and a small peri-
cardial effusion. Respiratory distress necessitated me-
chanical ventilation nearly throughout the infant’s life,
with the need for supplemental oxygen rising to 100%
at day 14. Progressive cardial and pleural effusions, as-
cites, and pulmonary and peripheral edemas led to death
at day 21. An autopsy was performed at 3 h postmortem.
Light microscopy demonstrated massive subplasmalem-
mal, non–membrane-bounded, PAS-positive, and amy-
lase-sensitive glycogen deposits in all tissues analyzed
(heart, diaphragm, vastus lateralis muscle, and liver).
Biochemically determined glycogen was also enhanced
markedly in heart (10.8%) and muscle (6.7%/9.9%
[normal 0.5%–2.0%]), and moderately in liver (7.0%
[normal 2.0%–6.0%]) and erythrocytes (15 mg/dl [nor-
mal 0–10 mg/dl]). Phk activity was undetectable in heart,
normal in muscle, slightly below the normal range in
liver, and slightly above the normal range in erythro-
cytes. Phosphorylase-a was moderately below the nor-
mal range in heart, muscle, and liver and was normal
in white blood cells; total phosphorylase was normal in
all samples. a-Glucosidase in leukocytes was normal.
Mutation Analysis
The study was approved by the ethics committee of
the University of Bochum Medical School. The complete
coding sequences of PHKA1, PHKA2, PHKB, PHKG1
(except patient C), CALM1-3, and PYGM were ampli-
fied by RT-PCR from total RNA purified from heart or
skeletal muscle autopsy samples from patients A–D. The
differentially spliced PHKA1 exons 27 and 28 (phos-
phorylation sites) and exon 19 (“a′ region”) were am-
plified, together with their flanking intron sequences,
from genomic DNA. The PHKG1 promoter regions (∼1
kb) of patients A–D, the coding exons and flanking in-
tron sequences of the PHKG1 gene of patient C, and
the coding exons and flanking intron sequences of the
PHKG2 genes of patients A–D were amplified from ge-
nomic DNA. All PCR products were analyzed by direct
cycle sequencing with Applied Biosystems reagents and
instruments. In addition, the intact overall organization
of the PHKG1 genes of patients A–D was confirmed by
bridging the four large introns by overlapping PCRs, and
normal lengths of these PCR products were verified by
agarose-gel electrophoresis. Mutation analysis of these
genes has been described in more technical detail else-
where: PHKA1, PHKB, PHKG1, CALM1-3, and PYGM
(Burwinkel et al. 2003); PHKA2 (Burwinkel et al. 1996);
and PHKG2 (Burwinkel et al. 1998). The PYGB coding
sequences of patients A–D were amplified from total
RNA (heart or skeletal muscle) in five overlapping in-
tervals between 30 nt upstream of the start codon and
43 nt downstream of the stop codon. The PRKAG2
coding sequences of patients A–E were amplified by RT-
PCR from RNA (2  1 overlapping intervals for the
long splice variant and 1  1 intervals for the short
splice variant) as well as by PCR from genomic DNA,
and the PCR products were sequenced. Mutations were
independently confirmed from RNA and genomic DNA.
Expression and Mutagenesis of AMPK Domains
and Subunits and Their Analysis
Isolated Bateman domains from AMPK-g2 were ex-
pressed as glutathione-S-transferase (GST) fusions in
bacteria, and heterotrimeric AMPK complexes were ex-
pressed in mammalian cells as described elsewhere (Scott
et al. 2004). All mutations were created using the Quik-
Change Site-Directed Mutagenesis system (Stratagene).
Binding of nucleotides and assays of AMPK were per-
formed as described elsewhere (Scott et al. 2004). Phos-
phorylation of Thr-172 on AMPK-a and of the AMPK
phosphorylation site on acetyl-CoA carboxylase (ACC)
was monitored with phosphospecific antibodies by use
of an infrared scanner, as described elsewhere (Hawley
et al. 2003).
Results
No Mutations in Phk and Glycogen Phosphorylase
Genes
No Phk isoform genes or differentially spliced exons
are known to be specifically expressed in the heart. There-
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Table 1
Mutation Analysis of Five Patients with Fatal Congenital Nonlysosomal Heart Glycogenosis and Low Phk Activity
GENE
VARIANT(S) FOUND IN PATIENT
Aa Bb Cb Da Eb
PHKA1 … … … … NA
PHKA2 … hemi. E38Qc … … NA
PHKB … … … … NA
PHKG1  promoter … … … … NA
PHKG2 … … … … NA
CALM1 … … … … NA
CALM2 … … … … NA
CALM3 … … … … NA
PYGM het. G21Sd, het. R414Ge … … … NA
PYGB … … het. A303Sf, het. D502Ng het. A303S, het. D502N NA
PRKAG2 het. R531Qh … … het. R531Qh het. R531Qh
NOTE.—Only nonsynonymous sequence variants are given. Numerous synonymous and intronic SNPs were also encountered; ellipses
indicate that no nonsynonymous sequence variants were found; hemi. p hemizygous (PHKA2 is X chromosomal); het. p heterozygous;
NA p not analyzed.
a Female.
b Male.
c Polymorphism (GAGrCAG; 112GrC): frequency 0.025; three heterozygotes and one homozygote found in 200 mostly female control
chromosomes (in the present study).
d Rare or unique sequence variant (GGCrAGC; 61GrA), not found in 200 control chromosomes analyzed (in the present study).
e Known polymorphism (CGGrGGG; 1240CrG) (dbSNP accession number rs11231866).
f Known polymorphism (GCCrTCC; 907GrT) (dbSNP accession number rs3818199).
g Known polymorphism (GATrAAT; 1504GrA) (dbSNP accession number rs2227891); S303 and N502 seem to be on the same allele,
since they cosegregate in family C with each other and with adjacent intronic polymorphisms and are also found in the same constellation
in patient D.
h Identical in patients A, D, and E (CGGrCAG; 1592GrA).
fore, the mutation search could not be targeted directly
to heart-specific Phk sequences. The muscle and liver iso-
form mRNAs of the a- and g-subunits are coexpressed
in comparable amounts in the heart, as are the three cal-
modulin genes (CALM1-3) and the muscle (PYGM) and
brain (PYGB) isoforms of glycogen phosphorylase (Kili-
mann 1997). A search of the current genome and EST
sequence databases, as well as our own experimental in-
vestigations (Burwinkel et al. 2003; the present study
[data not shown]), did not indicate the existence of ad-
ditional functional Phk subunit isoform genes or splice
variants. To account for the possibility that, for example,
certain missense mutations might affect the stability of—
or functional interactions within—the cardiac isoform
constellation of the Phk/phosphorylase protein complex
in an unanticipated, heart-specific, and possibly domi-
nant negative way, we analyzed the complete coding se-
quences of 10 candidate genes from patients A–D. How-
ever, we found no mutations or splicing abnormalities
(table 1 [see the note to table 1 and the “Discussion”
section for further comment]).
A Recurrent R531Q Mutation in the PRKAG2 Gene
of Three Patients
FHC/WPWS is a cardiac glycogenosis with familial
occurrence and a much less dramatic clinical manifes-
tation than that of our patient group. However, to see
whether our subjects might represent a particularly se-
vere variant of FHC/WPWS that is possibly associated
with a distinctive genotype, we analyzed the PRKAG2
gene. In patients A and D, and in the newly recruited
patient E, we found identical, heterozygous R531Q mis-
sense mutations (fig. 1). Parental DNA was available
only for patient E, but the R531Q mutation could be
detected in neither the mother nor the father, indicating
that it was a de novo mutation. This sequence variant
was not found in 190 control chromosomes.
Electron microscopy of cardiac tissue from the R531Q-
mutation–positive patient E showed massive, subsar-
colemmal, and intermyofibrillar deposition of nonly-
sosomal b-glycogen within enlarged myocytes (fig. 2).
Glycogen rosettes (a particles) could not be detected.
Sarcomeres were often multifocally destroyed, and some
fibers were totally degenerated. However, large amylo-
pectinlike polysaccharide aggregates, as reported in
adult patients with FHC/WPWS and PRKAG2 muta-
tions (Arad et al. 2002), were not observed.
Biochemical Characterization of the Mutant Protein
The R531Q mutation severely impairs AMP and ATP
binding by the g2-subunit.—Among the previously char-
acterized mutations, the most pronounced functional con-
sequences—both molecular (Daniel and Carling 2002;
Scott et al. 2004) and clinical—are associated with a dif-
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Figure 1 Heterozygous R531Q missense mutation underlying fatal congenital nonlysosomal heart glycogenosis. A typical sequencer readout
is shown (top). The high conservation of the mutant R531 residue is illustrated (middle) by alignments with the corresponding partial sequences
from CBS4 of the human (“Hs”) g1 and g3 isoforms, pig g3, and the Drosophila (“Dros”) and yeast AMPK paralogs. Alignments with partial
sequences from other CBS domains of g2 and g3, in which mutations were identified in the corresponding arginine residues or the adjacent
histidine residue, are shown (bottom). In the course of analysis of the PRKAG2 gene and cDNA, the following additional sequence features
were noted: (1) RT-PCR product sequences displayed partial deletion of codon 251 (apparently leaky splicing) at the beginning of exon 6 in
all five patients and a normal control individual and (2) SNPs include CDS-26CrT (allele frequencies: C, 0.89; T, 0.11 [ ]), Ex636insAnp 190
(allele frequency: A, 0.83 [ ]), and Ex10-42CrT (allele frequencies: C, 0.83; T, 0.17 [ ]).np 12 np 12
ferent replacement in the same amino acid position
(R531G), indicating that arginine 531 is of particular im-
portance. The R531G-positive patient displayed severe
arrhythmia since the age of 2 years but was still alive at
age 43 years (Gollob et al. 2001b). We therefore employed
the R531G mutant protein as an internal reference in the
biochemical experiments of the present study.
Binding of AMP and ATP was measured in vitro to
GST fusion proteins containing Bateman domains A and
B (GST-A/B [residues 274–569, CBS motifs 1–4]) or
Bateman domain B only (GST-B [residues 430–556, CBS
motifs 3–4]) of human g2 (Scott et al. 2004), with either
the normal arginine-531 residue, the R531Q mutation,
or the R531G mutation (fig. 3 and table 2). The GST-
B protein with the normal g2 sequence bound one mol-
ecule of the activating nucleotide, AMP, and the affinity
was reduced 16-fold by the R531G mutation, confirming
previous findings (Scott et al. 2004). The R531Q mu-
tation reduced the affinity for AMP even further (66-
fold). The mutations also reduced the affinity for the
inhibitory nucleotide ATP, and again the effect of R531Q
(23-fold) was stronger than that of R531G (4.5-fold).
The wild-type fusion protein containing both Bateman
domains (GST-A/B) bound two molecules of AMP with
high affinity and strong positive cooperativity, as ob-
served previously (Scott et al. 2004). When the data were
fitted to a two-site Hill plot model, the concentration
giving half-maximal binding (B0.5) was 71 mM, and the
Hill coefficient (h) was 1.8. The R531G mutant also
bound two molecules of AMP with positive cooperativ-
ity but with a B0.5 of 2.3 mM, 33-fold higher than that
for the wild type. The effect of the R531Q mutation was
even more extreme, with a 1100-fold increase in B0.5 and
a loss of cooperativity ( ). The loss of cooperativehp 0.7
binding is evident from the much lower slope of the
semilogarithmic plot in figure 3C. The results for ATP
binding were analogous. Whereas the R531G mutation
caused a 6-fold increase in the B0.5 for ATP but retained
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Figure 2 Image from electron microscopy of glycogen storage in myocardial fibers of R531Q-mutation–positive patient E. Large amounts
of free monodispersed b-glycogen (“Gl”) accumulate between the myofibrils and beneath the sarcolemma. Many sarcomeres appear to be
destroyed (arrows), and some fibers are totally degenerated (star). In most mitochondria (“M”), solitary vacuoles and electron-dense, thickened,
and disoriented cristae can be observed. Numerous endomembranaceous vacuoles (“V”), some of them containing lipid, are seen in fibers with
advanced degeneration (star). The scale bar is 1 mm.
cooperativity, with the R531Q mutation, the effect was
1200-fold, and cooperativity was lost.
The R531Q and R531G mutations abolish AMP ac-
tivation of the holoenzyme.—To assess the effect of the
R531Q mutation on AMP activation of the AMPK ho-
loenzyme, we expressed the wild-type, R531G-mutant,
and R531Q-mutant proteins of g2 in HEK-293 cells,
together with myc-tagged a1 and b1. The recombinant
complexes were immunoprecipitated using anti-myc an-
tibodies prior to assay. Extracts initially were made using
a “slow lysis” procedure that involves scraping the cells
off the culture plate, centrifuging them down, and re-
suspending them in lysis buffer. This procedure is known
to cause maximal phosphorylation of Thr-172 on the a-
subunit, because of undefined stresses occurring during
the cell harvesting (Daniel and Carling 2002), and it
allowed the effects of the mutations on allosteric acti-
vation by AMP to be observed independent of effects
on phosphorylation. As observed elsewhere (Scott et al.
2004), the wild-type a1b1g2 complex was activated 4-
fold by AMP, with a half-maximal effect (A0.5) at 19 mM
 11 mM (fig. 4). However, neither the R531G nor the
R531Q mutant was activated significantly by AMP up
to the maximal concentration of 100 mM (fig. 4), con-
sistent with the strongly reduced binding affinity of these
mutants for AMP (fig. 3). Instead, both mutants were
slightly inhibited by AMP, which may be due to com-
petition of AMP with ATP at the catalytic site on the
kinase domain. The higher AMP affinity of holoenzyme
activation, as compared with AMP binding to the iso-
lated Bateman domain construct GST-A/B, confirms pre-
vious findings (Scott et al. 2004) and suggests that the
integration of the Bateman domains into the holoenzyme
context enhances nucleotide affinity.
The R531Q and R531G mutations increase the basal
phosphorylation and activity of AMPK.—We next com-
pared the activities (in the absence of AMP) of recom-
binant a1b1g2 complexes that were prepared from
HEK-293 cells by the “rapid” and “slow” lysis proce-
dures (fig. 5A). The rapid lysis procedure involves lysing
the cells in situ on the culture plate, and we believe that
it preserves the phosphorylation status of AMPK that
existed in the intact cells better than does the slow lysis
procedure (Daniel and Carling 2002). Compared with
the wild type, there was a significant increase (2.3-fold)
in the basal activity (measured after rapid lysis) of the
R531G mutant and an even greater increase (3.5-fold)
in that of the R531Q mutant. Both mutants were further
activated by the slow lysis procedure, but relatively less
so than the wild-type enzyme, such that, after slow lysis,
the activities of all three were similar. The increased basal
activities of the R531G and R531Q mutants, as well as
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Table 2
Binding Parameters for AMP and ATP Measured with Wild-Type, R531G-Mutant,
and R531Q-Mutant GST Fusion Proteins Containing Bateman Domain(s) B or A/B
FUSION TYPE
AND PROTEIN Na
AMP ATP
Kd or B0.5
b h Kd or B0.5
b h
GST-B:
WT 1 97  7 … 396  34 …
R531G 1 1,570  120 … 1,790  130 …
R531Q 1 6,400  380 … 9,150  140
GST-A/B:
WT 2 71  5 1.8  .2 239  12 1.8  .2
R531G 2 2,340  220 1.4  .2 1,350  66 2.9  .3
R531Q 2 7,320  490 .7  .1 53,000  15,000 .5  .1
NOTE.—WT p wild type.
a N p number of binding sites assumed per protein molecule.
b All values (in mM) are shown as mean  SE of the mean. If a single binding
site is assumed ( ), the data were fitted to a simple binding equation Y p L/Np 1
(KdL), where “Y” represents fractional saturation and “L” represents ligand con-
centration; the value given in this column is Kd. Where two binding sites are assumed
( ), the data were fitted to the Hill equation, Y p 2 # Lh/(B0.5
hLh), and theNp 2
value given in this column is B0.5 (i.e., the concentration of ligand that gives half-
maximal binding).
the further increase after slow lysis, correlated with an
increased phosphorylation of Thr-172 on the a-subunit
(fig. 5B) and an increased phosphorylation of the down-
stream target, ACC (fig. 5C).
Discussion
A Recurrent R531Q Missense Mutation in PRKAG2
Causes a Severe Congenital, Rapidly Fatal,
Nonlysosomal Heart Glycogenosis
The present study identifies, for the first time, a mo-
lecular cause of congenital, rapidly fatal, nonlysosomal
cardiac glycogenosis. Strikingly, we found three identical
but independent heterozygous R531Q missense muta-
tions in PRKAG2, in three of the five sporadic cases, all
from diverse geographic origins. These findings extend
the clinical spectrum of PRKAG2 mutations toward a
very severe manifestation characterized by fetal onset (pre-
natal bradycardia was noted in all three patients, prompt-
ing preterm delivery by cesarean section, and prenatal
cardiomegaly was noted in one patient), extreme cardio-
megaly, and an infantile-fatal outcome. The R531Q-pos-
itive patients died of hemodynamic and respiratory failure
secondary to hypertrophic nonobstructive cardiomyop-
athy but also had WPWS-like conduction anomalies. In
patients with classic juvenile-/adult-onset FHC/WPWS,
arrhythmia usually dominates the clinical picture (also in
the few reported patients with symptomatic onset in early
childhood [Blair et al. 2001; Gollob et al. 2001b]), and
these patients virtually always survive into reproductive
age. It will be of interest to investigate whether other
PRKAG2 mutations associated with intermediate phe-
notypes can be found among children with hypertrophic
cardiomyopathy and electrophysiological abnormalities
(Strauss and Lock 2003; Arad et al. 2005). The pheno-
types of the three R531Q-positive infants were very uni-
form, and there was no other PRKAG2 mutation in our
group of five patients. Conversely, the R531Q mutation
has never been reported in patients with classic FHC/
WPWS, despite its tendency to arise recurrently, like the
R302Q mutation in classic FHC/WPWS (see below). In
accordance with this strict, mutually exclusive correlation
between genotype and clinical phenotype, the molecular
abnormalities of the R531Q mutant protein are more
pronounced than those of any other PRKAG2 mutants
characterized to date. Hence, the R531Q mutation by
itself appears to be sufficient to cause the distinctive, very
severe phenotype of its carriers, and neither the additional
sequence variants (mostly polymorphisms) in the PYGM
and PYGB genes of patients A and D (table 1) nor other,
unidentified elements of genetic background need to be
invoked.
All R531Q-positive infants were sporadic cases, and
analysis of the parents of patient E showed that R531Q
was a newly arisen mutation in this family (the only
family available for analysis). Given the complete pen-
etrance of PRKAG2 mutations even in the less-severe,
juvenile-/adult-onset FHC/WPWS, this suggests that
R531Q mutations invariably cause an infantile-fatal dis-
ease, are therefore not passed on by their carriers, and
always occur de novo. At the nucleotide level, these mu-
tations are GrA replacements in a CpG context (fig. 1),
which are known to occur at least 13-fold more fre-
quently than other single-nucleotide replacements in the
CG dinucleotide (Antonarakis et al. 2001). An identical
replacement in the analogous position of the first CBS
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Figure 3 Binding of AMP (panels A and C) and ATP (panels B and D) by fusion proteins between GST and the Bateman domain B of
g2 (“GST-B” [panels A and B]) or between GST and both Bateman domains (“GST-A/B” [panels C and D]). In panels A and B, data were
fitted to the binding model: Y p L/(KdL). In panels C and D, data were fitted to a two-site Hill plot model: Y p 2 # L
h/(B0.5
h  Lh). “Y”
represents fractional saturation, “L” represents ligand concentration, “B0.5” is the concentration of nucleotide that gives half-maximal binding,
and “h” is the Hill coefficient. Best-fit parameters were estimated using GraphPad Prism (GraphPad software), and the curves were generated
using the equation with those binding parameters.
motif (arginine 531 is in the fourth CBS motif), R302Q
(fig. 1), is the most common PRKAG2 mutation and has
also arisen recurrently but is associated with milder clin-
ical and molecular phenotypes (Gollob et al. 2001a,
2002; Arad et al. 2002; Daniel and Carling 2002; Scott
et al. 2004). The occurrence of the R531Q mutation in
a large proportion of cases with prenatal- or neonatal-
onset severe nonlysosomal cardiac GSD offers a rapid,
noninvasive diagnostic test in this fatal condition, and
its apparently obligate de novo occurrence has corre-
sponding implications for genetic counseling.
The clinical manifestation of PRKAG2 mutations is
restricted to the heart. However, the g2-subunit of AMPK
is expressed in many tissues, and, even in the heart, it
does not appear to be the predominant isoform, at least
in rodents (Cheung et al. 2000; Mahlapuu et al. 2003).
In patients with the severe R531Q mutation, glycogen
accumulation was indeed seen in tissues other than the
heart (patients D and E [see the “Case Reports” sec-
tion]). Detailed examination can also reveal glycogen
accumulation in noncardiac tissues in adult patients with
FHC/WPWS and with milder PRKAG2 mutations (Mur-
phy et al. 2005), and the systemic hypertension observed
in two kindreds with FHC/WPWS (Gollob et al. 2001a,
2001b) may likewise be an extracardial manifestation.
Specific aspects of the role of AMPK in cardiac metabolic
physiology, however, may cause a particularly pro-
nounced accumulation of glycogen in the heart.
The pronounced heart glycogenosis observed in pa-
tients with the R531Q mutation strengthens the view
that glycogen storage is the primary pathological con-
sequence of PRKAG2 mutations and that the conduc-
tion defects are secondary to this. This was first proposed
after histological investigation of heart tissues of patients
with FHC/WPWS and was corroborated by studies of
transgenic mice overexpressing the N488I mutant of g2
(Arad et al. 2002, 2003). The mice displayed massive
cardiac glycogen deposition, ventricular pre-excitation,
and an infiltration of the annulus fibrosus, which nor-
mally insulates the atria from the ventricles, by glycogen-
filled myocytes. It was proposed that this infiltration
gives rise to microscopic atrioventricular connections
and causes the conduction abnormalities in these mice,
in human patients with PRKAG2 mutations, and sim-
ilarly also in patients with other cardiac glycogenoses
(GSD II, GSD IIb, and GSD III) (Arad et al. 2002; Gollob
et al. 2002).
The glycogen that accumulates in the cardiomyocytes
of individuals with PRKAG2 mutations may in part be
of abnormal structure. In the hearts of five adult patients
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Figure 4 Activation of heterotrimeric a1b1g2 complexes ex-
pressed in HEK-293 cells, with extracts made using the slow lysis
procedure that causes maximal phosphorylation (Hardie et al. 2000).
The complexes contained either wild-type (“WT”) g2 or R531G and
R531Q mutations of g2 and were assayed in anti-myc immunopre-
cipitates at various concentrations of AMP. Data were fitted to the
following equation: ,{(stimulation#basal)basal}#[AMP]activityp basal A [AMP]0.5
where “basal” is the activity in the absence of AMP, “stimulation” is
the maximal stimulation by AMP, and “A0.5” is the concentration of
AMP that gives half-maximal activation. Best-fit parameters were es-
timated, and curves were generated as for figure 3.
with three different PRKAG2 mutations, Arad et al.
(2002) found large, amorphous, amylase-resistant amy-
lopectinlike polysaccharide aggregates, similar to those
observed in patients with GSD IV. It is conceivable that
the perturbation of AMPK function by these mutations
directly or indirectly upsets the balance of the different
enzyme activities that participate in glycogen synthesis
and degradation and thus affects the structure of the
branched glycogen polymer. However, in R531Q-mu-
tation–positive patients A and E, the glycogen deposits
were amylase sensitive (amylase was not applied in case
D), and electron microscopy of the cardiac tissue of pa-
tient E (fig. 2) revealed normal glycogen b particles, with
no evidence of the aggregates seen by Arad et al. (2002).
Neither were abnormal polysaccharide aggregates re-
ported in the hearts of transgenic mice overexpressing
the FHC/WPWS mutation N488I, although these mice
developed massive cardiac glycogenosis (Arad et al.
2003). The amylase-resistant molecular variant may be
a minor side product, inert to physiological turnover, of
the patients’ perturbed glycogen metabolism. It may ac-
cumulate only over the course of years or decades, and
therefore it may be apparent only in adult patients.
Genetic Heterogeneity of Fatal Congenital
Nonlysosomal Heart Glycogenosis
No mutations were found in patients B and C, either
in PRKAG2 or in the Phk and phosphorylase genes. The
hemizygous E38Q replacement in the PHKA2 gene of
patient B is a polymorphism also found in controls (in
both hetero- and homozygous constellations), and the
heterozygous A303S and D502N replacements in the
PYGB gene of patient C are common polymorphisms
also detectable in his healthy parents (see the note to
table 1). It remains to be seen whether the two PRKAG2
mutation–negative subjects are mutant in novel disease
genes or whether they represent unusually severe man-
ifestations of mutations in one of the other genes known
to give rise to GSDs involving the heart. Their PHKA2
and PYGB polymorphisms might have mild functional
consequences that aggravate the manifestation of a prin-
cipal defect in another gene or influence its tissue spec-
ificity (Hansen et al. 1995; Westphal et al. 2002).
When the phenotypes of the three R531Q-positive
subjects are compared with each other, with the two
mutation-negative subjects, and with the three first-pub-
lished cases of infantile-fatal nonlysosomal heart gly-
cogenosis with low Phk activity and undefined genotype
(Mizuta et al. 1984; Eishi et al. 1985; Servidei et al.
1988; Elleder et al. 1993), they all appear very similar.
All but patient C display extreme cardiomegaly (heart
weights 2.7–6.5-fold greater than normal), onset of car-
diac or respiratory distress from before birth to within
the first weeks of life, and death between age 3 wk and
age 5 mo. The R531Q-negative patient C is set apart by
a particularly malignant course and short lifespan (11
d), neurological symptoms, no WPWS-like ECG features
or cardiomegaly, and a family history suggestive of au-
tosomal recessive inheritance, probably reflecting a dif-
ferent genetic etiology of his condition.
The Existence of a Heart-Specific Primary Phk
Deficiency Is Doubtful
Low-to-zero Phk enzyme activities were determined
in heart autopsy samples from all five patients studied
here, leading to their tentative identification as heart-
specific Phk deficiency, an entity described previously
(Mizuta et al. 1984; Eishi et al. 1985; Servidei et al.
1988; Elleder et al. 1993). However, we found no mu-
tations or splicing abnormalities in three of the four
patients whose Phk genes were analyzed, and the hemi-
zygous E38Q replacement in the PHKA2 gene of the
fourth patient is an innocuous polymorphism. We can-
not exclude unusual mutation types not covered by our
approach (such as a mutation in a transcription factor
binding site affecting expression specifically in the heart),
but it appears most likely that the low Phk activities in
our patient group—and possibly in autopsy samples
from infantile-fatal heart glycogenosis cases, in gen-
eral—either are of secondary nature or are artifacts.
AMPK is not believed to regulate Phk directly, but it is
plausible that, in a metabolic status causing massive gly-
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Figure 5 AMPK activity (A), phosphorylation of Thr-172 on the
AMPK a-subunit (B), and phosphorylation of the downstream target
ACC (C) in HEK-293 cells expressing heterotrimeric a1b1g2 com-
plexes, with or without g2 mutations, as in figure 4. Cells were har-
vested by both the rapid and the slow lysis procedures, and AMPK
activities were measured in anti-myc immunoprecipitates in the ab-
sence of AMP. Data are means  SE of the mean, for results from
duplicate culture plates.
cogen deposition, the activity or expression of Phk is
down-regulated, so that low Phk activities in these cases
may be authentic but secondary. It is noteworthy that,
also in most patients with skeletal muscle glycogenosis
and low Phk activity, we could not detect mutations
either in Phk subunits or in PRKAG3 (the skeletal muscle
isoform of the AMPK g-subunit that is mutated in a
mild muscle glycogenosis in pigs [Milan et al. 2000])
(Burwinkel et al. 2003). Phk is a notoriously unstable
enzyme. In striated muscle tissues, it may be particularly
sensitive to inactivation (e.g., by dephosphorylation or
proteolysis). This could occur in vivo (i.e., in myopathic
tissue chronically damaged by another primary defect)
or after sampling (for further discussion, see the study
by Burwinkel et al. [2003]). In the cardiac cases, in par-
ticular, samples were always obtained through autopsy
several hours postmortem and would be particularly vul-
nerable to dephosphorylation or degradation.
The R531Q and R531G Mutations Reduce the AMP
and ATP Affinities but Enhance the Basal Activity
and Phosphorylation of AMPK
All seven previously identified mutations in the g2
gene that cause FHC/WPWS occur in the Bateman do-
main region (Gollob et al. 2002; Oliveira et al. 2003).
Three of them (R302Q, R531G, and H383R) affect res-
idues in (R302Q and R531G) or adjacent to (H383R)
equivalent positions in the first, second, and fourth CBS
motifs (fig. 1). These, together with a fourth mutation
(T400N), cause defects in the binding of AMP and ATP
to isolated Bateman domains, as well as defects in ac-
tivation of the a1b1g2 complexes by AMP (Daniel and
Carling 2002; Scott et al. 2004). A fifth mutation that
inserts a leucine residue between the first and second
CBS motif has only a weak effect, if any, on these pa-
rameters (Daniel and Carling 2002; Scott et al. 2004),
and the remaining two (Y487H and N488I) have not
yet been tested. On the basis of structural modeling of
the Bateman domains from g2, we have proposed that
the basic residues affected by the mutations are involved
with binding of the phosphate group of AMP (Scott et
al. 2004). Of the five PRKAG2 mutants previously
tested, the R531G mutation caused the most severe de-
fect in the binding of AMP and ATP to the GST fusion
containing both Bateman domains (Scott et al. 2004),
as well as the most severe defect in AMP activation of
the intact heterotrimeric complex (Daniel and Carling
2002; Scott et al. 2004). Here, we show that the R531Q
mutation causes even more severe defects in the binding
of AMP and, especially, ATP. Binding of AMP or ATP
to the construct containing both Bateman domains is
highly cooperative ( ), indicating that one of thehp 2
sites is inaccessible to AMP until the nucleotide is bound
to the other site. One explanation of the severe nature
of mutations in Bateman domain B (R531G and R531Q)
may be that this is the domain that binds the nucleotides
first, so that mutations in this domain impair the binding
of both molecules of the nucleotide. The R531Q mu-
tation additionally reduces or abolishes the cooperative
interactions between the two binding sites. The exten-
sion of our knowledge of Bateman domain mutations
also has implications for the understanding of other
Bateman domain–containing proteins, including several
proteins involved in hereditary disorders, as well as for
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the design of drugs that target AMPK, for example, in
type 2 diabetes (Kemp 2004; Scott et al. 2004).
Most, if not all, PRKAG2 mutations impair or abolish
activation of the AMPK complex by AMP (i.e., they
cause a loss of function). However, a loss-of-function
mechanism is hard to reconcile with the dominant nature
of these mutations, especially given a background of one
wild-type g2 allele plus the coexpressed g1 isoform (un-
der the assumption that the AMPK holoenzyme is an
abg heterotrimer with no potential for dominant neg-
ative interactions between mutant and wild-type g-sub-
units within a single holoenzyme complex). Arad et al.
(2002) suggested, on the basis of equivalent mutations
in the budding yeast homologue of the AMPK g-subunits
(Snf4), that two of the mutations (T400N and N488I)
caused constitutive activation of the AMPK complex.
Direct analysis of g mutant proteins in mammalian cells
has yielded conflicting results. Coexpression of an R70Q
mutant in g1 (equivalent to the R302Q mutant in g2)
with a1 and b1 in COS7 cells was reported to cause an
increase in basal phosphorylation and activity of AMPK
(Hamilton et al. 2001). Also, the coexpression of the
R225Q mutant of g3 (equivalent to R70Q in g1 and to
R302Q in g2 [see fig. 1]) with a2 and b2 in COS cells
led to an increase in basal activity and a-subunit phos-
phorylation (Barnes et al. 2004). Results from studies
of transgenic mice overexpressing either the R225Q mu-
tant g3-subunit in skeletal muscle (Barnes et al. 2004)
or the N488I mutant g-subunit in the heart (Arad et al.
2003) also indicated increases in the basal activities of
the mutant, compared with the wild-type enzymes. In
contrast to these results, analysis of four (Daniel and
Carling 2002) or five (Scott et al. 2004) FHC/WPWS
mutations in human g2, which are coexpressed with a1
and g1 in CCL13 cells, exhibited reduced or absent ac-
tivation by AMP but no evidence of an increase in the
basal activity.
In the present study, we have reinvestigated the effect
of the R531G mutation (as well as the R531Q mutation)
on AMPK activity by studying expression in HEK-293,
instead of CCL13, cells. Although the R531G and R531Q
mutations both completely abolished AMP activation of
the AMPK complex (fig. 4), they also caused an increase
in the basal phosphorylation and activity of the hetero-
trimeric AMPK complex, determined using the rapid lysis
method that we believe preserves the phosphorylation
state (fig. 5). The latter was not observed in two previous
studies of the R531G mutant (Daniel and Carling 2002;
Scott et al. 2004), but this can now be ascribed to the use
of CCL13 cells. Although originally derived from human
liver (Chang 1954), the CCL13 cells available from the
American Type Culture Collection are now thought to
have resulted from contamination with HeLa cells (see
the American Type Culture Collection Web site). Unlike
HEK-293 cells, HeLa cells do not express the major up-
stream kinase for AMPK (i.e., LKB1) (Hawley et al.
2003), and we have now verified that CCL13 cells do not
express LKB1 either (data not shown). We also confirmed
(data not shown) that the increase in basal phosphory-
lation and activity, caused by the R531G and R531Q
mutations when coexpressed with a1 and b1 in HEK-
293 cells, is not observed upon expression in HeLa cells.
Thus, the increased basal phosphorylation is observed
only in cells expressing LKB1.
How can an increase in basal AMPK activity lead to
glycogen storage? Activation of AMPK increases glucose
uptake by causing acute activation or translocation, as
well as increased expression, of both GLUT1 and GLUT4
(Hayashi et al. 1998; Kurth-Kraczek et al. 1999; Barnes
et al. 2002; Fryer et al. 2002) in several tissues, including
the heart (Russell et al. 1999). Although AMPK also
phosphorylates the muscle isoform of glycogen synthase
both in cell-free assays (Carling and Hardie 1989) and
in vivo (Jørgensen et al. 2004) at a site that causes in-
activation of the enzyme (Flotow and Roach 1989), the
inactivation caused by phosphorylation at this site is
overridden by high concentrations of the allosteric ac-
tivator, glucose-6-phosphate (Flotow and Roach 1989).
Increased glucose uptake caused by an elevated basal
activity of AMPK over an extended period, in the ab-
sence of a proportional increase in consumption of glu-
cose, may cause increased intracellular glucose-6-phos-
phate, leading to persistent allosteric activation of
glycogen synthase and inhibition of glycogen phospho-
rylase. Increased glycogen content in the hearts of trans-
genic mice overexpressing wild-type g2 (Arad et al.
2003) and reduced glycogen resynthesis in skeletal mus-
cles of g3-knockout mice after exercise (Barnes et al.
2004) also indicate that AMPK activity enhances glycogen
synthesis; these data support the view that PRKAG2 dis-
ease mutations cause glycogen storage through basal ac-
tivation of AMPK.
Correlations between Genotype, Molecular Properties,
and Clinical Manifestation
The molecular properties of the mutant AMPK pro-
teins can, in general terms, be correlated with their bio-
logical effects: the increase in the basal phosphorylation
and activity of AMPK caused by disease mutations in
PRKAG2 explains the dominant, gain-of-function–like
character of these mutations, and the R531Q mutation
is associated with both the most severe clinical pheno-
type and the most severe molecular abnormalities of all
known PRKAG2 mutations. Yet, on closer inspection,
we are left with paradoxes that indicate that we are still
far from a coherent understanding of the molecular
mechanisms of AMPK and of its physiology and patho-
physiology in the heart; the particular severity of the
R531Q mutation highlights these gaps in understanding.
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Concerning the gain- versus loss-of-function issue, it
remains striking that most disease-causing mutations
have a specific impact on AMP and ATP affinity and
occur very selectively—and even recurrently (R302Q
and R531Q)—in strategic positions within the CBS mo-
tifs or in linker sequences between the motifs. In con-
trast, no mutations have been found in other parts of
the g-subunit or in the a- or b-subunits (Oliveira et al.
2003). This indicates a specific connection between nu-
cleotide binding and the pathological effects of these
mutations. However, it is believed that the phosphory-
lation of the a-subunit at Thr-172 occurs subsequent to
AMP binding. It is therefore unclear how the observed
increase of phosphorylation and basal activity in the
rapid lysis cell culture system is brought about if the
mutant proteins cannot bind AMP at physiological con-
centrations. This contradiction might be resolved if the
mutations not only reduced nucleotide affinity but also
simultaneously were “AMP-mimetic” (i.e., if they in-
duced a more active conformation of the Bateman do-
mains, even when no AMP is bound).
Of all the PRKAG2 mutations characterized to date,
R531Q has the strongest effect on nucleotide binding
and basal activation, but there is no abrupt transition
in the nature of the molecular impacts between the
R531G and R531Q mutations (figs. 3, 4, and 5). In
contrast, the clinical phenotype of patients with R531Q
is dramatically more severe than that of patients with
the other mutations associated with classic FHC/WPWS,
including R531G. The two patient groups differ strik-
ingly in terms of (1) age at onset, course, and outcome;
(2) degree of cardiomegaly; (3) the fact that hemodyn-
amic and respiratory failure, as opposed to arrhythmia
and conduction anomalies, dominate the clinical picture;
and (4) in sporadic versus familial occurrence reflecting
the profound difference in survival. It is possible that
the molecular parameter in which the R531Q protein
differs most markedly from the other mutants—and
which most faithfully correlates with the biological im-
pact of PRKAG2 mutations in general—has not yet been
characterized. In this context, the R109insL mutation is
also of interest, because it only slightly affects AMP
binding (Scott et al. 2004) but still results in a severe
adult phenotype (Blair et al. 2001); it may affect a mech-
anistic step between AMP binding and basal activation.
There are two known molecular effects in which
R531Q is indeed unique among the PRKAG2 mutations
characterized to date: it abolishes the cooperativity of
nucleotide binding, and it has a particularly large impact
on ATP binding. The latter effect makes the R531Q
mutant the only g2 mutant protein that is probably un-
occupied by either AMP or ATP under in vivo condi-
tions, whereas the wild type and the other mutant g2-
subunits are predicted to be occupied by ATP under
resting conditions. The R531Q-mutant g2-subunit, un-
occupied by ATP, might be in a partially active confor-
mation. If this is correct, AMPK might be regarded an
“ATP-inhibited” as much as an “AMP-activated” ki-
nase. Another aspect that deserves consideration is the
highly cooperative, “ultrasensitive” response of AMPK,
through which a small increase in the AMP:ATP ratio
over a critical range of concentrations can translate into
a strong activation of AMPK (Hardie et al. 1999). Shift-
ing this narrow “window of sensitivity” to different de-
grees by different mutations could thus lead to pro-
foundly nonlinear consequences. Also, the overexpres-
sion of the wild type and the N488I mutant g2-subunits
at similar levels in transgenic mice led to a much more
severe phenotype in the N488I mice (Arad et al. 2003).
All these observations suggest that the underlying path-
omechanism is a form of AMPK dysregulation specifi-
cally connected with its interaction with AMP and ATP,
which subsequently leads to an increase of basal phos-
phorylation and activity by the upstream kinase. How-
ever, the detailed molecular mechanisms linking the two
phenomena remain to be fully elucidated.
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